A coalition of 340B providers, patient and rural advocates is pressing HHS to act against drug manufacturers they say are either limiting access to 340B pricing or threatening providers to give them data, both of which the coalition says violate 340B statute and shouldn’t be condoned by HHS. The coalition’s request comes as House appropriators express concerns in their fiscal 2021 HHS spending bill report that “HRSA is not using their existing oversight authority to pursue balanced oversight of both...